In 2009, the following standards and interpretations with relevance for Novozymes were brought into effect and implemented:
The implementation of these has led to further specifications in the Notes, but no changes in recognition and measurement except that borrowing costs relating to qualifying assets DKK 7 million must be capitalized from 2009 pursuant to IAS 23, but comparative figures need not be restated. The Statement of comprehensive income is new and includes items previously shown in the Statement of shareholders’ equity. In addition, IFRS 3 now requires that acquisition costs are expensed and makes it possible to use the full goodwill method.
Standards and interpretations issued by IASB but not adopted by the EU and therefore not implemented as at December 31, 2009, comprise:
Implementation of these will lead to further specifications in the Notes but no material changes in recognition and measurement.